B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30
B. Riley Securities analyst Mayank Mamtani reiterates Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $26 to $30.
Stocks · News reference
Climb Bio shares are trading higher after Beijing Mabworks Biotech announced the dosing of the first patient in a Phase 2 trial for immunoglobulin A nephropathy in China, conducted in collaboration with Climb Bio.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Maintains Buy on Climb Bio, Raises Price Target to $32
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $32.
Baird Maintains Outperform on Climb Bio, Raises Price Target to $25
Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.
Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule
Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA nephropathy candidate into Phase 3.